The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Effects of Protease Inhibitors on Hyperglycemia, Hyperlipidemia, and Lipodystrophy: A 5-Year Cohort Study
Abstract
BACKGROUND: Although human immunodeficiency virus (HIV)-related morbidity and mortality rates in patients with advanced HIV infection who are treated with combination antiretroviral drugs have declined, significant metabolic adverse effects associated with these regimens have been increasingly recognized. However, since data from patients studied before and after initiation of protease inhibitor (PI) therapy are scant, the true effect of PIs on these metabolic changes remains unknown. OBJECTIVES: To examine temporal trends in serum glucose and lipid levels after initiation of PI therapy, to assess whether changes are independent of virological response and improvement in disease severity, and to determine risk factors associated with the development of hyperglycemia, hyperlipidemia, and lipodystrophy. METHODS: A 5-year historical cohort analysis in a population of 221 HIV-infected patients observed in the Infectious Diseases Clinic of a tertiary care center from October 1, 1993, through July 31, 1998. Clinical and laboratory data were retrieved from medical records and a computerized database. The main outcome measure was the incidence of hyperglycemia, hypercholesterolemia, hypertriglyceridemia, and lipodystrophy. Adjusted incidence rate ratios (IRRs) were estimated by means of Poisson regression. In addition, mixed regression analyses were performed to examine effects of PIs on serum lipid and glucose levels, modeled as continuous outcomes. RESULTS: The cumulative incidence of new-onset hyperglycemia, hypercholesterolemia, hypertriglyceridemia, and lipodystrophy was 5%, 24%, 19%, and 13%, respectively. Most of these events occurred after initiation of PI therapy. Protease inhibitors were independently associated with hyperglycemia (adjusted IRR, 5.0; 95% confidence interval [CI], 1. 3-19.4), hypercholesterolemia (adjusted IRR, 2.8; 95% CI, 1.5-5.2), hypertriglyceridemia (adjusted IRR, 6.1; 95% CI, 3.1-11.7), and lipodystrophy (adjusted IRR, 5.1; 95% CI, 1.9-13.9). Anabolic steroids and psychotropic medications were also associated with lipodystrophy. Inclusion of potential intermediate variables (eg, virological suppression and increase in body weight) did not reduce the magnitude of the association with PIs. The association between hypertriglyceridemia and ritonavir was stronger than for other PIs (Wald test, P=.02). In contrast, the incidence of hyperglycemia, hypercholesterolemia, and lipodystrophy did not vary significantly across different PIs. Longitudinal mixed models confirmed that serum lipid levels were more substantially affected by antiretroviral therapy, particularly PIs, than serum glucose levels. Similarly, controlling for surrogate markers did not abolish the strong association between PIs and increase in serum lipid levels. CONCLUSION: We found an independent association between PI use and hyperglycemia, hyperlipidemia, and lipodystrophy that is not explained by the antiviral and therapeutic effect of PIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Self-citationCarr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,246
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,885
Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08468-2 · Cited by 1,495
SERUM CHOLESTEROL, BLOOD PRESSURE, AND MORTALITY: IMPLICATIONS FROM A COHORT OF 361 662 MEN
Martin, M., Browner, W., Hulley, S., Kuller, L., & Wentworth, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90597-0 · Cited by 1,120
Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03391-1 · Cited by 1,065 · cited 1×
“With regard to the cause of the lipodystrophy, it has been speculated that interference of PIs with apoptosis and impaired differentiation of peripheral adipocytes but relative sparing of intra-abdominal adipocytes is the underlying mechanism.(28) The occurrence of hyperlipidemia as the primary metabolic change may co…”
BackgroundVisceral abdominal-fat accumulation associated with use of indinavir
Miller, K. D., Jones, E., Yanovski, J. A., Shankar, R., Feuerstein, I., & Falloon, J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11518-5 · Cited by 700
Association of Diabetes Mellitus and Chronic Hepatitis C Virus Infection
Mason, A. L., Lau, J. Y., Hoang, N., Qian, K., Alexander, G. J., Xu, L., Guo, L., Jacob, S., Regenstein, F. G., Zimmerman, R., et al. (1999) · Hepatology · doi:10.1002/hep.510290235 · Cited by 659
Lowering blood cholesterol to prevent heart disease
Hupp, J. R. (1985) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/0278-2391(85)90208-3 · Cited by 644
Danner, S. A., Carr, A., Leonard, J. M., Lehman, L. M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., Pintado, V., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332303 · Cited by 567
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
Cameron, D. W., Heath-Chiozzi, M., Danner, S., Cohen, C., Kravcik, S., Maurath, C., Sun, E., Henry, D., Rode, R., Potthoff, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)04161-5 · Cited by 536
Serum Cholesterol in Young Men and Subsequent Cardiovascular Disease
Klag, M. J., Ford, D. E., Mead, L. A., He, J., Whelton, P. K., Liang, K.-Y., & Levine, D. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302043280504 · Cited by 516
Severe premature coronary artery disease with protease inhibitors
Henry, K., Melroe, H., Huebsch, J., Hermundson, J., Levine, C., Swensen, L., & Daley, J. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79053-x · Cited by 513
A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection
Markowitz, M., Saag, M., Powderly, W. G., Hurley, A. M., Hsu, A., Valdes, J. M., Henry, D., Sattler, F., Marca, A. L., Leonard, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512073332204 · Cited by 493
Abdominal obesity and the development of noninsulin‐dependent diabetes mellitus
Björntorp, P. (1988) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610040607 · Cited by 294
Indinavir-associated lipodystrophy
Viraben, R., & Aquilina, C. (1998) · AIDS · doi:10.1097/00002030-199806000-00001 · Cited by 271
Neaton, J. D., Kuller, L. H., Wentworth, D., & Borhani, N. O. (1984) · American Heart Journal · doi:10.1016/0002-8703(84)90669-0 · Cited by 261
Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey.
Isles, C. G., Hole, D. J., Gillis, C. R., Hawthorne, V. M., & Lever, A. F. (1989) · BMJ · doi:10.1136/bmj.298.6678.920 · Cited by 173
Role of Free Fatty Acids in Glucose Homeostasis
Ruderman, N. B., Toews, C. J., & Shafrir, E. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130081012 · Cited by 147
Classification and Diagnosis of Diabetes Mellitus
GENUTH, S. M. (1982) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)31358-x · Cited by 140
Cited by
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Friis-Møller, N., Weber, R., Reiss, P., Thiébaut, R., Kirk, O., Monforte, A. D., Pradier, C., Morfeldt, L., Mateu, S., Law, M., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00010 · Cited by 1,077
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Brown, T. T. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1179 · Cited by 851
Feinstein, M. J., Hsue, P. Y., Benjamin, L. A., Bloomfield, G. S., Currier, J. S., Freiberg, M. S., Grinspoon, S. K., Levin, J., Longenecker, C. T., Post, W. S., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000695 · Cited by 658
Metadata
- Authors
- Tsiodras, S., Mantzoros, C., Hammer, S., & Samore, M.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2000-07-10
- Volume
- 160
- Issue
- 13
- Pages
- 2050
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2015990374
- Cited by
- 452
- References
- 22
- FWCI
- 48.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.